Shares of Laboratory Corporation of America Holdings (NYSE:LH) have been assigned a consensus rating of “Buy” from the fourteen analysts that are currently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $168.30.

A number of analysts recently weighed in on the stock. Zacks Investment Research raised shares of Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating and set a $170.00 price objective on the stock in a research report on Tuesday. KeyCorp reissued a “hold” rating on shares of Laboratory Corporation of America Holdings in a research report on Tuesday, September 26th. ValuEngine lowered shares of Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Barclays PLC increased their price objective on shares of Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a research report on Thursday, July 27th. Finally, Robert W. Baird reissued a “hold” rating on shares of Laboratory Corporation of America Holdings in a research report on Sunday, September 17th.

COPYRIGHT VIOLATION NOTICE: “Laboratory Corporation of America Holdings (LH) Receives Consensus Rating of “Buy” from Analysts” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/10/12/laboratory-corporation-of-america-holdings-lh-receives-consensus-rating-of-buy-from-analysts.html.

In other news, CEO David P. King sold 44,687 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $156.86, for a total transaction of $7,009,602.82. Following the transaction, the chief executive officer now directly owns 258,753 shares of the company’s stock, valued at $40,587,995.58. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider F Samuel Eberts III sold 31,500 shares of the firm’s stock in a transaction that occurred on Friday, August 25th. The stock was sold at an average price of $155.22, for a total transaction of $4,889,430.00. Following the transaction, the insider now directly owns 31,894 shares in the company, valued at $4,950,586.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 222,968 shares of company stock worth $34,980,922. Corporate insiders own 0.90% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in Laboratory Corporation of America Holdings by 2.3% during the second quarter. Vanguard Group Inc. now owns 10,361,891 shares of the medical research company’s stock valued at $1,597,181,000 after buying an additional 231,600 shares during the period. BlackRock Inc. increased its holdings in Laboratory Corporation of America Holdings by 3,602.5% during the first quarter. BlackRock Inc. now owns 8,074,378 shares of the medical research company’s stock valued at $1,158,430,000 after buying an additional 7,856,297 shares during the period. State Street Corp increased its holdings in Laboratory Corporation of America Holdings by 2.4% during the first quarter. State Street Corp now owns 4,639,813 shares of the medical research company’s stock valued at $665,669,000 after buying an additional 109,170 shares during the period. Boston Partners increased its holdings in Laboratory Corporation of America Holdings by 4.8% during the second quarter. Boston Partners now owns 4,590,372 shares of the medical research company’s stock valued at $707,560,000 after buying an additional 210,138 shares during the period. Finally, Nordea Investment Management AB increased its holdings in Laboratory Corporation of America Holdings by 2.0% during the second quarter. Nordea Investment Management AB now owns 2,696,851 shares of the medical research company’s stock valued at $415,693,000 after buying an additional 54,100 shares during the period. 93.19% of the stock is currently owned by institutional investors.

Laboratory Corporation of America Holdings (LH) opened at 149.28 on Thursday. Laboratory Corporation of America Holdings has a one year low of $119.51 and a one year high of $164.22. The stock has a market cap of $15.20 billion, a P/E ratio of 20.91 and a beta of 0.92. The company’s 50-day moving average price is $153.60 and its 200-day moving average price is $148.80.

Laboratory Corporation of America Holdings (NYSE:LH) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.47 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.40 by $0.07. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The company had revenue of $2.50 billion for the quarter, compared to analyst estimates of $2.47 billion. During the same period in the prior year, the company posted $2.36 EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Analysts forecast that Laboratory Corporation of America Holdings will post $9.53 EPS for the current fiscal year.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Analyst Recommendations for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.